Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous somatostatin for prevention of post-ERCP pancreatitis
IRCT20191231045969N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Somatostatin plus rectal diclofenac with Placebo plus rectal diclofenac (2 arms). Primary endpoint: Acute pancreatitis after ERCP. Started Aug 2018; status: completed.
02
Drugs
somatostatindiclofenac
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on IRCT20191231045969N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191231045969N1.